Skip to main content
    G

    GeneDx Holdings Corp. (WGS)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ

    $51.02
    -1.35 (-2.58%)

    Market Cap: $1.57B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    GeneDx Holdings Corp. (WGS) P/E Ratio & Valuation History

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    GeneDx Holdings (WGS) trades at 340.1x trailing earnings and 3.3x sales. Its P/S of 3.3x is below its 5-year median of 3.8x. Its forward P/E is 38.8x.

    Current Multiples

    Its forward P/E is below its trailing P/E, which implies earnings per share about 776.5% higher over the next year.

    MultipleValue
    P/E (trailing)340.1x
    Forward P/E38.8x
    Price to sales3.3x
    Price to book6.2x
    PEGN/A
    FCF yield-6.6%
    As of Nov 17, 2026

    Historical Medians

    MultipleCurrent5-year median10-year median
    P/S3.3x3.8xN/A
    P/B6.2x2.8xN/A
    Medians of month-end values through Oct 2026: 50 to 59 months (5-year).

    Valuation History

    Over the 4 of the 6 year ends shown that have a P/S, its P/S ranged from 0.3x in 2023 to 8.5x in 2025. 2025 was the highest of those years.

    Year endPriceP/EP/SP/B
    2025$130.0692.9x8.5x11.3x
    2024$76.86313.3x6.7x8.5x
    2023$2.75N/A0.3x0.3x
    2022$8.71N/A0.4x0.4x
    2021$147.19N/AN/A2.8x
    2020$364.36N/AN/AN/A
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewOvervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About WGS

    What is WGS's forward P/E ratio?

    GeneDx Holdings has a forward P/E ratio of 38.8x.

    Is WGS stock overvalued?

    GNG's valuation label for WGS is Overvalued.

    What is WGS's price to sales ratio?

    GeneDx Holdings has a price to sales ratio of 3.3x.